At just 50.38% efficacy, China’s covid-19 vaccine far less effective than initially reported
In a major setback to be the dominant vaccine supplier to developing countries, Brazilian researchers announced that China’s Sinovac vaccine was far less effective than originally touted.According to data made available by Brazil's Butantan Institute, a São Paulo-based public institute, the efficacy of Sinovac’s CoronaVac in a late- stage trials was at just 50.38 percent, nearly 30 percentage points lower than what the initial data showed.The Butantan Institute initially said that late-stage trials had found the CoronaVac vaccine to be between 78 percent and 100 effective.After a number of scientists accused the trial’s organizers of misleading the public, the institute revealed researchers had separated the cases into six categories: asymptomatic, very mild, mild, two levels of moderate, ...